David T Pointer1, Jordan A McDonald2, Samer A Naffouje3, Rutika Mehta3, Jason B Fleming3, Jacques P Fontaine4, Gregory Y Lauwers5, Jessica M Frakes6, Sarah E Hoffe6, Jose M Pimiento3. 1. Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA. 2. MD Program, Morsani College of Medicine, University of South Florida Health, Tampa, Florida, USA. 3. Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 4. Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 5. Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 6. Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Abstract
BACKGROUND AND OBJECTIVES: The gold standard for locoregional esophageal cancer (LEC) treatment includes preoperative chemoradiation and surgical resection, with possible perioperative or adjuvant systemic therapy. With few data associating histologic grade and prognosis in LEC patients receiving neoadjuvant chemoradiation followed by resection, we seek to evaluate this association. METHODS: Our institutional esophagectomy database between 1999 and 2019 was queried, selecting esophageal adenocarcinoma patients who completed neoadjuvant therapy (NAT), followed by esophagectomy. Propensity-score matching of low- and high-histologic grade groups was performed to assess survival metrics using initial clinical grade (cG) and final pathologic grade (pG). We performed a multivariable logistic regression to study predictors of pathologic complete response as a secondary objective. RESULTS: A total of 518 patients met the inclusion criteria. Kaplan-Meier analysis of the matched dataset showed no difference in initial or 5-year recurrence-free survival or overall survival (OS) between cG1 and cG2 versus cG3 based on original grade. When matched according to pG, cG1-2 had improved median survival parameters compared to cG3, with 5-year OS for cG1-2 of 45% versus 27% (p = 0.001). Higher pG, pathologic N stage, and poor response to NAT are predictors of poor survival. CONCLUSION: Patients with post-NAT pG1-2 demonstrated improved survival. Integrating histologic grade into postneoadjuvant staging may be warranted.
BACKGROUND AND OBJECTIVES: The gold standard for locoregional esophageal cancer (LEC) treatment includes preoperative chemoradiation and surgical resection, with possible perioperative or adjuvant systemic therapy. With few data associating histologic grade and prognosis in LEC patients receiving neoadjuvant chemoradiation followed by resection, we seek to evaluate this association. METHODS: Our institutional esophagectomy database between 1999 and 2019 was queried, selecting esophageal adenocarcinoma patients who completed neoadjuvant therapy (NAT), followed by esophagectomy. Propensity-score matching of low- and high-histologic grade groups was performed to assess survival metrics using initial clinical grade (cG) and final pathologic grade (pG). We performed a multivariable logistic regression to study predictors of pathologic complete response as a secondary objective. RESULTS: A total of 518 patients met the inclusion criteria. Kaplan-Meier analysis of the matched dataset showed no difference in initial or 5-year recurrence-free survival or overall survival (OS) between cG1 and cG2 versus cG3 based on original grade. When matched according to pG, cG1-2 had improved median survival parameters compared to cG3, with 5-year OS for cG1-2 of 45% versus 27% (p = 0.001). Higher pG, pathologic N stage, and poor response to NAT are predictors of poor survival. CONCLUSION: Patients with post-NAT pG1-2 demonstrated improved survival. Integrating histologic grade into postneoadjuvant staging may be warranted.
Authors: P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast Journal: N Engl J Med Date: 2012-05-31 Impact factor: 91.245
Authors: J Freilich; S E Hoffe; K Almhanna; W Dinwoodie; B Yue; W Fulp; K L Meredith; R Shridhar Journal: Dis Esophagus Date: 2014-03-17 Impact factor: 3.429
Authors: G Tomasello; F Petrelli; M Ghidini; E Pezzica; R Passalacqua; F Steccanella; L Turati; G Sgroi; S Barni Journal: Eur J Surg Oncol Date: 2017-03-18 Impact factor: 4.424
Authors: Daniel C Fernandez; Sarah E Hoffe; James S Barthel; Shivakumar Vignesh; Jason B Klapman; Cynthia Harris; Khaldoun Almhanna; Matthew C Biagioli; Kenneth L Meredith; Vladimir Feygelman; Nikhil G Rao; Ravi Shridhar Journal: Pract Radiat Oncol Date: 2012-03-30
Authors: Thomas W Rice; Donna M Gress; Deepa T Patil; Wayne L Hofstetter; David P Kelsen; Eugene H Blackstone Journal: CA Cancer J Clin Date: 2017-05-26 Impact factor: 508.702
Authors: Milan Vošmik; Jan Laco; Igor Sirák; Josef Dvořák; Petr Lochman; Miroslav Hodek; Petra Malá; Stanislav Rejchrt; Rudolf Repák; Michal Leško; Alexander Ferko; Aleš Ryška; Bohuslav Melichar; Jiří Petera Journal: Pathol Oncol Res Date: 2017-05-27 Impact factor: 3.201
Authors: T Valentin; A Le Cesne; I Ray-Coquard; A Italiano; G Decanter; E Bompas; N Isambert; J Thariat; C Linassier; F Bertucci; J O Bay; A Bellesoeur; N Penel; S Le Guellec; T Filleron; C Chevreau Journal: Eur J Cancer Date: 2016-01-26 Impact factor: 9.162
Authors: David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: Karyn A Goodman; Fang-Shu Ou; Nathan C Hall; Tanios Bekaii-Saab; Briant Fruth; Erin Twohy; Michael O Meyers; Daniel J Boffa; Kisha Mitchell; Wendy L Frankel; Donna Niedzwiecki; Anne Noonan; Yelena Y Janjigian; Paul J Thurmes; Alan P Venook; Jeffrey A Meyerhardt; Eileen M O'Reilly; David H Ilson Journal: J Clin Oncol Date: 2021-06-02 Impact factor: 50.717